BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

BIND Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update

August 6, 2015

- Preliminary interim data from iNSITE 1 clinical trial remains on track for fourth quarter of 2015 -

- Second Accurin candidate, AZD-2811, to enter clinic in fourth quarter of 2015 -

- Progress made developing next-generation Accurin product concepts for multiple therapeutic areas -

- Management to host conference call today at 8:30 a.m. EDT -

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

August 6, 2015

- Phase 2 study initiated for lead microbiome therapeutic SER-109 for prevention of recurrent Clostridium difficile infection (CDI) in adults

- FDA Breakthrough Therapy Designation received for SER-109

- Successfully completed initial public offering 

Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results

Acceleron Pharma Reports Second Quarter 2015 Financial and Operational Results

August 6, 2015

- Completed luspatercept myelodysplastic syndromes phase 2 clinical trial -

- FDA Fast Track Designations granted to luspatercept for the treatment of patients with beta-thalassemia -

- Phase 3 clinical trials with luspatercept in lower risk myelodysplastic syndromes and beta-thalassemia expected to begin by year-end 2015 -

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

August 6, 2015

Global Phase 3 Registration-enabling Studies on Track to Begin in Second Half of 2015 for AG-221 & First Half of 2016 for AG-120

Phase 1 Expansion Studies for AG-221 & AG-120 Programs Ongoing

CAMBRIDGE, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the second quarter ended June 30, 2015.

Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum

Editas Medicine Named A 2015 Technology Pioneer by World Economic Forum

August 5, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced that it has been selected as a 2015 Technology Pioneer by the World Economic Forum. Editas is among 49 companies being recognized with this distinguished award for advancing the world’s most innovative technologies.

T2 Biosystems Reports 2015 Second Quarter Results

T2 Biosystems Reports 2015 Second Quarter Results

August 4, 2015

LEXINGTON, Mass., Aug. 4, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems (NASDAQ:TTOO) today reported operating highlights and financial results for the second quarter ended June 30, 2015. Recent operational highlights included:

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Company Update

August 5, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2015. “We are pleased with the continued progress of our pipeline over the last quarter. In particular, we are encouraged by the progress Avanir has made with AVP-786 in 2015.

National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury

National Institute of Nursing Research Uses Quanterix’s Simoa Technology to Identify the Significance of Key Protein in Long-term Complications Caused by Traumatic Brain Injury

August 3, 2015

Study identifies the correlation of tau accumulation in military personnel to those who experienced long-term neurological symptoms after a TBI; findings to be used to identify patients who are most at risk

Quanterix Named Final Winner of NFL and GE Head Health Challenge I

Quanterix Named Final Winner of NFL and GE Head Health Challenge I

July 23, 2015

GE and the NFL award Quanterix with $500,000 grant to fund advancements in measuring the long-term effects of brain injury in athletes using its Simoa technology

Denali Therapeutics Appoints Carole Ho, M.D., as Chief Medical Officer and Head of Development

Denali Therapeutics Appoints Carole Ho, M.D., as Chief Medical Officer and Head of Development

July 22, 2015

SOUTH SAN FRANCISCO, Calif., July 22, 2015 /PRNewswire-USNewswire/ -- Denali Therapeutics Inc. ("Denali"), a biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that Carole Ho, M.D., has joined the company as Chief Medical Officer and Head of Development. In this role, Dr. Ho will lead the translational and clinical development activities at Denali and serve on the Executive Leadership Team.